Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Exanthema × Erlotinib Hydrochloride × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 299 Lung Neoplasms 107 Pancreatic Neoplasms 69 Neoplasms 53 Neoplasm Metastasis 31 Brain Neoplasms 31 Squamous Cell Carcinoma of Head and Neck 25 Head and Neck Neoplasms 25 Breast Neoplasms 25 Glioblastoma 24 Adenocarcinoma of Lung 23 Gliosarcoma 22 Non-Squamous Non-Small Cell Lung Cancer 18 Colorectal Neoplasms 18 Carcinoma, Hepatocellular 17 Adenocarcinoma, Bronchiolo-Alveolar 16 Rectal Neoplasms 13 Colonic Neoplasms 13 Carcinoma, Renal Cell 13 Glioma 12 Esophageal Neoplasms 11 Astrocytoma 11 Central Nervous System Neoplasms 9 Carcinoma, Squamous Cell 9 Salivary Gland Neoplasms 8 Prostatic Neoplasms 8 Oligodendroglioma 8 Gallbladder Neoplasms 8 Adenocarcinoma 8 Ovarian Neoplasms 7

Interventions

Gels 2 Fulvestrant 2 Doxycycline 2 Dapsone 2 ruxolitinib 1 dexpanthenol 1 ceterizine hydrochloride 1 capivasertib 1 benralizumab 1 Triamcinolone Acetonide 1 Tetracycline 1 Sirolimus 1 Provitamins 1 Prednisone 1 Panitumumab 1 Minocycline 1 Loperamide 1 Irinotecan 1 IFL protocol 1 Hydrocortisone 1 Erlotinib Hydrochloride 1 Clindamycin 1 Cetuximab 1 Anti-Bacterial Agents 1 Alpelisib 1 Acitretin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00473083 2017-04-04

LUTRAERL

British Columbia Cancer Agency

Phase 2 Completed

150 enrolled 13 charts

Exanthema, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡